

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Anakinra for treating Still's disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No. It was identified that in systemic onset juvenile arthritis anakinra is approved via NHS England clinical commissioning policy for treatment where macrophage activation syndrome is present. It was suggested that if similar provision is not made in adult onset Still's disease there is inequality between the treatment of children and adults with the same condition given that SJIA and AOSD are considered to be the same disease.

However, anakinra is used outside of its marketing authorisation for macrophage activation syndrome. NICE can only appraise technologies within their marketing authorisations, so this is not an issue that the committee can address in this appraisal.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, section 3.12 (none identified)

**Approved by Associate Director (name):** .....Ross Dent.....

**Date:** 14/12/2020

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
Not applicable.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
---

Section 3.12 of the FAD (none identified)

**Approved by Associate Director (name):** Ross Dent

**Date:** 02/02/21